Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Interim results from a phase 1/2 precision medicine study of PLX8394- a next...

Dr Filip Janku - The University of Texas MD Anderson Cancer Center USA

Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor ( Dr Filip Janku - The University of Texas MD Anderson Cancer Center USA )

SIOG COVID-19 working group report and discussion of ethical issues

Dr Nicolò Battisti - The Royal Marsden NHS Foundation Trust, London, UK

SIOG COVID-19 working group report and discussion of ethical issues ( Dr Nicolò Battisti - The Royal Marsden NHS Foundation Trust, London, UK )

OncoAlert and ecancer weekly roundup for November 2 - 7, 2020

Dr Gil Morgan - Skåne University Hospital, Lund, Sweden

OncoAlert and ecancer weekly roundup for November 2 - 7, 2020 ( Dr Gil Morgan - Skåne University Hospital, Lund, Sweden )

Evolving concepts in the diagnosis and staging of multiple myeloma

Dr Jens Hillengass - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Evolving concepts in the diagnosis and staging of multiple myeloma ( Dr Jens Hillengass - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

Recommendations on treating multiple myeloma patients during the pandemic

Dr Jens Hillengass - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Recommendations on treating multiple myeloma patients during the pandemic ( Dr Jens Hillengass - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non...

Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-small cell lung cancer ( Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France )

PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer

Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer ( Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France )

Sotorasib for advanced non-small cell lung cancer

Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

Sotorasib for advanced non-small cell lung cancer ( Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France )

CaRE2 Cancer Research Link©: Social Determinants of Health on Cancer Outcomes...

Kenneth Stokes, Lynette Jones and Dr Herman Tucker

CaRE2 Cancer Research Link©: Social Determinants of Health on Cancer Outcomes in Black Populations ( Kenneth Stokes, Lynette Jones and Dr Herman Tucker )

VHL/HIF and VEGF inhibitors in clear cell renal cell carcinoma

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

VHL/HIF and VEGF inhibitors in clear cell renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Prospective validation of single mouse testing by the paediatric preclinical...

Dr Peter Houghton - Greehey Children's Cancer Institute, San Antonio, USA

Prospective validation of single mouse testing by the paediatric preclinical testing consortium ( Dr Peter Houghton - Greehey Children's Cancer Institute, San Antonio, USA )

Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of...

Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA

Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients ( Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA )

More from ecancer